ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Enlaza Therapeutics, which specializes in what it calls “covalent protein biologics,” has raised $100 million in series A funding. JPMorgan Chase’s life sciences group led the round, and Amgen Ventures and Regeneron Ventures contributed as well. Enlaza’s platform, called War-Lock, produces “therapeutic warheads” that the company says can bind to drug targets with high specificity. Enlaza says the funding will be used to further develop its platform and bring its drug candidates closer to clinical trials.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X